We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

46 hedge funds and large institutions have $50.5M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more call options, than puts

Call options by funds: $441K | Put options by funds: $133K

127% more capital invested

Capital invested by funds: $22.2M → $50.5M (+$28.3M)

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

21% more funds holding

Funds holding: 38 → 46 (+8)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
46
Holders Change
+8
Holders Change %
+21.05%
% of All Funds
0.79%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
8
Reduced
8
Closed
7
Calls
$441K
Puts
$133K
Net Calls
+$308K
Net Calls Change
+$225K

Top Buyers

Rank Fund Capital Flow
1
ACM
Athyrium Capital Management
New York
+$12.5M
2
ACM
AIGH Capital Management
Maryland
+$1.27M
3
UOC
UBS O'Connor
Illinois
+$537K
4
WVP
Worth Venture Partners
New Jersey
+$361K
5
Millennium Management
Millennium Management
New York
+$222K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$133K
2
Morgan Stanley
Morgan Stanley
New York
-$92.4K
3
TC
Titleist Capital
Texas
-$39.2K
4
Charles Schwab
Charles Schwab
California
-$37.7K
5
Prudential Financial
Prudential Financial
New Jersey
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$32K +$30.1K +15,483 New
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$31K +$28.5K +14,663 New
Two Sigma Advisers
28
Two Sigma Advisers
New York
$30K -$6.41K -3,300 -19%
Charles Schwab
29
Charles Schwab
California
$28K -$37.7K -19,391 -59%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$25K – – –
Marshall Wace
31
Marshall Wace
United Kingdom
$24K +$22K +11,300 New
E
32
Ergoteles
New York
$23K +$21.2K +10,927 New
UBS Group
33
UBS Group
Switzerland
$23K +$21.7K +11,169 +4,964%
SWA
34
SFMG Wealth Advisors
Texas
$21K – – –
WJWM
35
Williams Jones Wealth Management
New York
$21K – – –
Citigroup
36
Citigroup
New York
$18K +$16.2K +8,356 New
TVWM
37
Tower View Wealth Management
Wisconsin
$9K – – –
Barclays
38
Barclays
United Kingdom
$6K +$5.54K +2,849 New
Bank of America
39
Bank of America
North Carolina
$4K +$3.34K +1,719 +171,900%
HNB
40
Huntington National Bank
Ohio
$3K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$2K – – –
IA
42
IFP Advisors
Florida
$2K +$594 +306 New
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$1K +$408 +210 +250%
TFP
44
Tilia Fiduciary Partners
North Carolina
$1K +$845 +435 New
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$15 – – –
Prudential Financial
46
Prudential Financial
New Jersey
– -$34K -25,000 Closed
Two Sigma Investments
47
Two Sigma Investments
New York
– -$30K -22,413 Closed
EGM
48
Engineers Gate Manager
New York
– -$30K -21,870 Closed
Group One Trading
49
Group One Trading
Illinois
– -$3.89K -2,000 Closed
Simplex Trading
50
Simplex Trading
Illinois
– -$3.1K -1,598 Closed
1
2
3

RVLP Hedge Fund Activity: Q3 2022 in Review

46 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2022, worth a combined $50.5M — up 127% from $22.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RVLP positions and 7 closed out — a net gain of 8 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Athyrium Capital Management, adding an estimated $12.5M. The largest seller was Renaissance Technologies, cutting an estimated $133K.

  • 46 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2022, up from 38 in Q2 2022.
  • Funds reported $50.5M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2022, up 127% quarter-over-quarter.
  • 15 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2022 and 7 closed out, a net change of +8 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2022 was Athyrium Capital Management, an estimated $12.5M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2022 was Renaissance Technologies, an estimated $133K sold.

Based on aggregated 13F filings for Q3 2022.